3-(哌嗪-1-基)丙酸乙酯 | 43032-38-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 3-(哌嗪-1-基)丙酸乙酯
• 中文别名: 1-哌嗪基丙酸乙酯；3-(哌嗪-1-基)丙 酸乙酯
• 英文名称: ethyl 3-(piperazin-1-yl)propanoate
• 英文别名: ethyl 3-(piperazin-1-yl)propionate；3-piperazin-1-yl-propionic acid ethyl ester；1-(2-ethoxycarbonylethyl)piperazine；3-Piperazino-propionsaeure-ethylester；ethyl 3-piperazin-1-ylpropanoate
• CAS: 43032-38-8
• 化学式: C₉H₁₈N₂O₂
• 分子量: 186.254
• InChiKey: XCLNGVSHLDOGFR-UHFFFAOYSA-N

物化性质

• 沸点：
  89-93°C/0.8mm
• 密度：
  1.011±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  3-(哌嗪-1-基)丙酸乙酯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 3-[4-(2-Pyridin-4-yl-2,8-diaza-spiro[4.5]decane-8-carbonyl)-piperazin-1-yl]-propionic acid ethyl ester
  参考文献：
  名称：

  Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes

  摘要：

  The synthesis and biological activity of analogues containing spiro piperidinylpyridine and pyrrolidinylpyridine templates are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the spiro structures as central template for nonpeptide RGD mimics. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00095-1
• 作为产物：
  描述：

  3-溴丙酸乙酯 在 盐酸 、 potassium carbonate 作用下， 以 乙酸乙酯 、 乙腈 为溶剂， 反应 16.0h， 生成 3-(哌嗪-1-基)丙酸乙酯
  参考文献：
  名称：

  [EN] TARGETING CHIMERIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF
  [FR] COMPOSÉ CHIMÈRE DE CIBLAGE, COMPOSITION PHARMACEUTIQUE LE COMPRENANT, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 靶向嵌合化合物、含其的药物组合物及其制备方法和用途

  摘要：

  一种靶向嵌合化合物、含其的药物组合物及其制备方法和用途。该靶向嵌合化合物如通式(I)所示，且通式(I)中的各取代基同说明书中的定义相同。与现有技术中的氟维司群相比，该靶向嵌合化合物对雌激素受体α有着相当甚至更优的对突变耐药细胞的增殖抑制活性，从而有望对治疗显示出相当甚至更好的疗效。

  公开号：

  WO2022161166A1

文献信息

• Compounds and Their Use in Treating Cancer
  申请人：AstraZeneca AB

  公开号：US20190194190A1

  公开（公告）日：2019-06-27

  The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R 1 , R 4 , R 5 , R 6 , R 7 , Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

  本说明书一般涉及公式(I)的化合物： 以及药学上可接受的盐和前药，其中R1、R4、R5、R6、R7、Linker、X、Y、A、G、D和E具有此处定义的任何含义。本说明书还涉及将此类化合物以及药学上可接受的盐和前药用于治疗人体或动物体的方法，例如用于预防或治疗癌症。本说明书还涉及制备此类化合物涉及的工艺和中间化合物，以及含有它们的药物组合物。
• Carboxylic acid derivatives, medicaments comprising these compounds,
  申请人：Karl Thomae

  公开号：US05994356A1

  公开（公告）日：1999-11-30

  The present invention relates to carboxylic acid derivatives of the general formula ##STR1## in which R.sub.a to R.sub.c, A, B, D, E and X.sub.1 to X.sub.3 are as defined in claim 1, their tautomers, their stereoisomers including their mixtures, and their salts, in particular their physiologically tolerated salts with inorganic or organic acids or bases, which have useful pharmacological properties, preferably aggregation-inhibiting inhibiting actions, medicaments containing these compounds, their use and processes for their preparation.

  本发明涉及一般式##STR1##的羧酸衍生物，其中R.sub.a至R.sub.c，A，B，D，E和X.sub.1至X.sub.3如权利要求1所定义，它们的互变异构体，它们的立体异构体包括它们的混合物，以及它们的盐，特别是它们与无机或有机酸或碱的生理耐受盐，具有有用的药理特性，优选具有聚集抑制作用的药物，含有这些化合物的药物，它们的用途和制备方法。
• [EN] SIGMA RECEPTOR BINDERS<br/>[FR] LIANTS DE RÉCEPTEUR SIGMA
  申请人：UNIV TEXAS

  公开号：WO2017190107A1

  公开（公告）日：2017-11-02

  Provided herein, inter alia, are compounds and methods of treating diseases including cancer, neurological disease, alcohol withdrawal, depression and anxiety, traumatic brain injury, and neuropathic pain.

  本文提供了治疗疾病的化合物和方法，包括癌症、神经系统疾病、酒精戒断、抑郁和焦虑、创伤性脑损伤以及神经病痛。
• Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5′-sulfonamide moiety of a phenyl ring
  作者：Dae-Kee Kim、Ju Young Lee、Namkyu Lee、Do Hyun Ryu、Jae-Sun Kim、Sukho Lee、Jin-Young Choi、Je-Ho Ryu、Nam-Ho Kim、Guang-Jin Im、Won-Son Choi、Tae-Kon Kim

  DOI：10.1016/s0968-0896(01)00200-0

  日期：2001.11

  alkoxy group (R) of the phenyl ring, the sulfonamide type (X), and the length of the methylene chain linking the carboxylic acid, and the results were discussed in detail. From this study, we have clearly demonstrated that introduction of a carboxylic acid group to the 5'-sulfonamide moiety of the phenyl ring greatly enhanced PDE5 inhibitory activity, probably by mimicking the phosphate group of cGMP

  由易得的起始化合物6a-b和环胺3-5按三步顺序制备在苯环9a-1的5'-磺酰胺中具有羧酸基的新西地那非类似物。在酶测定中，已证明所有目标化合物9a-1在抑制5型磷酸二酯酶（PDE5）方面比西地那非更有效4-3-4倍。通过改变苯环的烷氧基（R），磺酰胺类型（X）和连接羧酸的亚甲基链的长度来研究对IC（50）值的影响，并详细讨论了结果。从这项研究中，我们已经清楚地证明，在苯环的5'-磺酰胺部分引入羧酸基团会大大增强PDE5的抑制活性，可能是通过模仿cGMP的磷酸基团。哌啶基丙酸衍生物9i具有更高的PDE5抑制活性，与西地那非相比，具有比PDE同工酶更好的选择性，已被选择用于更详细的生物学研究。
• Heteroatom-Substituted Analogues of Orphan Nuclear Receptor Small Heterodimer Partner Ligand and Apoptosis Inducer (<i>E</i>)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic Acid
  作者：Zebin Xia、Lulu Farhana、Ricardo G. Correa、Jayanta K. Das、David J. Castro、Jinghua Yu、Robert G. Oshima、John C. Reed、Joseph A. Fontana、Marcia I. Dawson

  DOI：10.1021/jm200051z

  日期：2011.6.9

  (E)-4[3'-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces the cell cycle arrest and apoptosis of cancer cells. Because its pharmacologic properties solubility, bioavailability, and toxicity required improvement for translation, structural modifications were made by introducing nitrogen atoms into the cinnamyl ring and replacing its E-double bond with XCH2 (X = O, N, and S) with the objective of enhancing these properties without impacting apoptosis-inducing activity. Analogues having nitrogen atoms in heterocyclic rings corresponding to the cinnamyl phenyl ring displayed equal or higher biological activities. The pyrimidine and pyridine analogues were more soluble in both phosphate-buffered saline and water. While the 2,5-disubstituted pyridine analogue was the most potent inducer of KG-1 acute myeloid leukemia cell apoptosis, on the basis of apoptotic activity in KG-1 cells and solubility, the 2,5-disubstituted pyrimidine proved to be the more promising candidate for treatment of acute myeloid leukemia.

  (E)-4([3'-亚胺基-4'-羟基苯基])3-氯丙烯酸包围苯环诱导癌细胞周期阻滞和凋亡。为了改进其药理活性，如溶解度、生物利用度和毒性，引入了氮原子到苯环的羟基取代位点，并将双键改 became XCH2（X = O，N，S），以提高药理活性/毒性。具有含N原子的杂环对应于表间环部分的类药物显示了相等或更高的生物活性。而含有嘌呤的对位的二甲苯碱和二甲基并环二甲苯碱相当容易在磷酸缓冲盐和水这些易溶溶剂中暴漏。其中，二甲苯并二取代的苯碱类药物是最有效诱导粒流感-1（KG-1）急性髓系白血病细胞凋亡的药物。基于对粒流感-1细胞的凋亡作用和社会性，二苯基苯碱似乎在急性髓系白血病治疗方面是一个更为有前途的候选药物。